Mankind Pharma Ltd.

NSE: MANKIND | BSE: 543904

Expensive Performer

Download real time

2355.00 -4.20 (-0.18%)

330.2K NSE+BSE Volume

NSE 06 Jun, 2025 3:03 PM (IST)

97,184

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Mankind Pharma Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Mankind Pharma Ltd. from all sources in a single place.

Load latest

Mankind Pharma Ltd.

07 Aug 2024

2355.00

-0.18%

Company Update

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation of participation in Investors Meeting

Mankind Pharma Ltd.

06 Aug 2024

2355.00

-0.18%

Earnings Call

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Investor Conference Call for Q1FY25- Transcript

Mankind Pharma Ltd.

06 Aug 2024

2355.00

-0.18%

Company Update

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Credit Rating

BSE India

Intimation of reaffirmation of Credit Rating

Mankind Pharma Ltd.

04 Aug 2024, 10:39PM

2355.00

-0.18%

Acquisition of BSV to aid future growth of Mankind Pharma: V-C Juneja

Business Standard

The acquisition of Bharat Serums and Vaccines would add a lot of value, aiding future growth of Mankind Pharma, according to Vice Chairman and Managing Director Rajeev Juneja. On July 25, Mankind had announced that it will fully acquire Bharat Serums and Vaccines (BSV) from Advent International for an enterprise value of around Rs 13,630 crore. "One thing should be very clear, this acquisition is not to really add some kind of revenue, but to add a lot of value, future growth, entry barrier, super specialty business in Mankind," Juneja said in an analyst call. Whatever the company is paying for BSV, it is very relevant as the company has "so much of value" with well established business, he said. The acquisition is in line with the company's strategy of buying high entry barrier businesses, he stated. The buyout will solidify Mankind's position with complementary drug portfolio and extensive reach to target rapidly growing highly under-penetrated markets, especially in fertility,

Mankind Pharma Ltd. has an average target of 2784.33 from 3 brokers.

Mankind Pharma Ltd.

02 Aug 2024

2355.00

-0.18%

Company Update

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation of participation in Investors Meeting

Mankind Pharma Ltd.

02 Aug 2024

2355.00

-0.18%

Earnings Call

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

BSE India

Transcript of Conference Call held on July 26, 2024 in relation to acquisition of 100% stake in Bharat Serums and Vaccines Limited

Mankind Pharma Ltd.

01 Aug 2024

2355.00

-0.18%

Company Update

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper Publication of Consolidated Unaudited Financial Results of the Company for the quarter ended on June 30, 2024

Mankind Pharma Ltd.

31 Jul 2024

2355.00

-0.18%

Earnings Call

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

BSE India

Investor Conference Call for Q1FY25- Audio Recording

Mankind Pharma Ltd.

31 Jul 2024

2355.00

-0.18%

Company Update

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation of participation in Investors meeting

Mankind Pharma Ltd.

31 Jul 2024

2355.00

-0.18%

Mankind Pharma Q1 results: Profit up 9.9% at Rs 543 cr; revenue rises 12%

Business Standard

Mankind also announced a rise in its prescriber penetration to 83.2 per cent in Q1 FY25, from 82.7 per cent in the same quarter last financial year

Mankind Pharma Ltd. is trading below all available SMAs

Mankind Pharma Q1 Results: Rising Exports Boost Revenue, But Margin Contracts

NDTV Profit | 31 Jul 2024 1 more

RESEARCH REPORTS

Buy SEE REPORTS >

Accumulate SEE REPORTS >